Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Metronidazole-Associated Encephalopathy
NEJM 374:1465, Baden, L.R., 2016
Rifaximin Treatment in Hepatic Encephalopathy
NEJM 362:1071-1081, 1140, Bass,N.M.,et al, 2010
Acute Hepatic Encephalopathy: Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Findings, and Correlation With Plasma Ammonia Level and Clinical Outcome
AJNR 31:1471-1479, McKinney,A.M.,et al, 2010
Levetiracetam as a Possible Cause of Fulminant Liver Failure
Neurol 71:685-686, Tan,T.C.H.,et al., 2008
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Valproate Therapy and Nonalcoholic Fatty Liver Disease
Ann Neurol 55:729-732, Luef,G.J.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Reye's Syndrome in the United States from 1981 Through 1997
NEJM 340:1377-1382,1423, Belay,E.D.,et al, 1999
Multisystem Hypersensitivity Reaction to Lamotrigine
Neurol 53:1367, Sarris,B.M.&Wong,J.G., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998
Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998
Lamotrigine-Associated Anticonvulsant Hypersentivitiy Syndrome
Neurol 51:1171-1175, Schlienger,R.G.,et al, 1998
Tasmar (tolcapone) Labeling Revisions of Package Insert
Roche Laboratories, , 1998
Seizures in Medically Complex Patients
Epilepsia 38:S55-S59, Boggs,J.G., 1997
Complications of Intravenous Gammaglobulin in Neuromuscular and other Disease
Muscle & Nerve 19:388-391996., Bertorini,T.E.,et al, 1996
Valproic Acid Hepatic Fatalities. III. U. S. Experience Since 1986
Neurol 46:465-469, Bryant,A.E.&Dreifuss,F., 1996
Felbamate-Associated Fatal Acute Hepatic Necrosis
Neurol 46:1457-1459, O'Neil,M.G.,et al, 1996
Fulminant Hepatic Failure Induced by Lamotrigine
BMJ 311:292, Makin,A.J.,et al, 1995
Anticonvulsant Hypersensitivity Syndrome
Arch Int Med 155:2285-2290, Vittorio,C.C.&Muglia,J.J., 1995
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Eosinophilia-Myalgia Syndrome, A Clinical Case Series of 21 Patients
Arch Int Med 151:533-537, Philen,R.M.,et al, 1991
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
Dantrolene Sodium and Hepatic Injury
Neurol 40:1427-1432, Chan,C.H., 1990
Tetrahydroaminoacridine (THA) in Alzheimer's Disease, Not Ready for Routine Use
BMJ 298:845-846, Graham,T.R.&Lewis,C.T., 1989
Sodium Valproate
Editorial, Lancet 2:1229-12311988., , 1988
Hypoglycemia:Causes, Neurological Manifestations, & Outcome
Ann Neurol 17:421-430, Malouf,R.,et al, 1985
Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Looking Beyond the Usual
Delhi J Ophthal doi:7869/djo.555, Shakrawal, J.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
NEJM 376:2011-2020, Devinsky, O.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016